Amplia has today announced that patient recruitment for the third cohort is now complete.
Participants in the ACCENT trial receive a dose of AMP945 given in combination with standard-of-care chemotherapy, in the treatment of advanced pancreatic cancer. After 1 month of treatment, the trial’s Safety Committee will review the clinical data to determine next steps in the trial.
Amplia’s CEO and Managing Director Dr Chris Burns commented:
“This achievement reflects the enthusiasm and commitment of the clinical trial sites in Melbourne, Sydney and Brisbane which has allowed recruitment for this cohort to be completed within one month of opening enrolment. As always, we thank the patients for consenting to be part of the trial.”
Click here to read today’s ASX release.